UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Neuropsychopharmacology (New York, N.Y.), 2015-07, Vol.40 (8), p.2025-2037

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder

The journal of clinical psychiatry, 2012-07, Vol.73 (7), p.953

2012

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

Current medical research and opinion, 2013-03, Vol.29 (3), p.217-226

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

Psychiatry and clinical neurosciences, 2018-02, Vol.72 (2), p.64-72

2018

Link zum Volltext

Verfügbarkeit prüfen

A Meta-Analysis of Randomized, Placebo-Controlled Trials of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

European neuropsychopharmacology, 2016-06, Vol.26 (6), p.979-993

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder

The journal of clinical psychiatry, 2015-05, Vol.76 (5), p.575

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia

Schizophrenia research, 2019-02, Vol.204, p.289-294

2019

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder

The journal of clinical psychiatry, 2015-05, Vol.76 (5), p.583

2015

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

Psychopharmacology, 2015-06, Vol.232 (12), p.2061-2070

2015

Link zum Volltext

Verfügbarkeit prüfen

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction

Journal of sexual medicine, 2015-10, Vol.12 (10), p.2036-2048

2015

Link zum Volltext

Verfügbarkeit prüfen

Ecopipam for Tourette Syndrome: A Randomized Trial

Pediatrics (Evanston), 2023-02, Vol.151 (2), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

The international journal of neuropsychopharmacology, 2013-03, Vol.16 (2), p.313-321

2013

Link zum Volltext

Verfügbarkeit prüfen

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

European neuropsychopharmacology, 2012-12, Vol.22 (12), p.847-857

2012

Link zum Volltext

Verfügbarkeit prüfen

Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis

CNS spectrums, 2016-10, Vol.21 (5), p.367-378

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

International clinical psychopharmacology, 2014-01, Vol.29 (1), p.36

2014

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

Neuropsychopharmacology (New York, N.Y.), 2016-11, Vol.41 (12), p.2961-2961

2016

Link zum Volltext

Verfügbarkeit prüfen

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

Human psychopharmacology, 2014-01, Vol.29 (1), p.64-72

2014

Link zum Volltext

Verfügbarkeit prüfen

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

International clinical psychopharmacology, 2015-09, Vol.30 (5), p.255

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial

Journal of affective disorders, 2017-10, Vol.221, p.275-282

2017

Link zum Volltext

Verfügbarkeit prüfen

Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials

CNS spectrums, 2020-06, Vol.25 (3), p.1-362

2020

Link zum Volltext

Verfügbarkeit prüfen

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

European neuropsychopharmacology, 2012-12, Vol.22 (12), p.858-866

2012

Link zum Volltext

Verfügbarkeit prüfen

A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder

Basic & clinical pharmacology & toxicology, 2016-05, Vol.118 (5), p.344-355

2016

Link zum Volltext

Verfügbarkeit prüfen

Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders

Journal of managed care & specialty pharmacy, 2015-09, Vol.21 (9), p.742

2015

Link zum Volltext

Verfügbarkeit prüfen

The Safety and Tolerability Profile of Vortioxetine in the Treatment of Patients With Major Depressive Disorder Aged 65 Years and Older

The American journal of geriatric psychiatry, 2014-03, Vol.22 (3), p.S143-S144

2014

Link zum Volltext

Verfügbarkeit prüfen

It's only a little ice: a personal view with companion commentary

Innovations in clinical neuroscience, 2012-02, Vol.9 (2), p.21-25

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(43)
Buchkapitel
(1)

Sprache

Englisch
(44)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(25)
Psychiatry
(24)
Adult
(21)
Male
(18)
Middle Aged
(18)
Female
(17)
Neurosciences & Neurology
(16)
Double-Blind Method
(15)
Treatment Outcome
(14)
Clinical Neurology
(13)
Depressive Disorder, Major - Drug Therapy
(13)
Pharmacology & Pharmacy
(11)
Psychiatric Status Rating Scales
(11)
Piperazines - Adverse Effects
(10)
Piperazines - Therapeutic Use
(10)
Sulfides - Adverse Effects
(10)
Sulfides - Therapeutic Use
(10)
Vortioxetine
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder

Randomized, double‐blind, placebo‐controlled 8‐week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder

A Meta-Analysis of Randomized, Placebo-Controlled Trials of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder

A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia

A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction

Ecopipam for Tourette Syndrome: A Randomized Trial

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder

Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial

Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: a phase 3, randomized controlled trial

Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States

A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder

Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders

The Safety and Tolerability Profile of Vortioxetine in the Treatment of Patients With Major Depressive Disorder Aged 65 Years and Older

It's only a little ice: a personal view with companion commentary

Suchergebnisse filtern